STROMMEN JACK B. 4

What Happened
Jack B. Strommen, a director of BioLargo, Inc. (BLGO), was granted a derivative award on 2026-03-31: an option covering 92,593 shares. The option was issued as payment for $15,000 in board fees under the Issuer’s 2024 Equity Incentive Plan. The filing lists the transaction as an award/derivative (code A); no exercise price was reported in the Form 4, though the footnote indicates the share count was determined by dividing the $15,000 fee amount by the option's exercise price (implying an exercise price of roughly $0.16 per share).

Key Details

• Transaction date: 2026-03-31; Form 4 filed: 2026-04-01 (no late filing indicated).
• Transaction type: Award / derivative grant (Option) covering 92,593 shares.
• Consideration: Issued in lieu of $15,000 in director fees under the 2024 Equity Incentive Plan.
• Exercise price: Not stated on the Form 4; footnote implies exercise price = $15,000 / 92,593 ≈ $0.16.
• Shares owned after transaction: Not specified in the filing.
• Footnote: The option was issued as payment for board services and the share count equals fees due divided by the option’s exercise price.

Context
This was a compensation award (an option grant), not an open-market purchase or sale. Such grants are common for board fees and do not by themselves indicate the director is buying or selling shares on the market. The filing does not indicate exercise, sale, or immediate cashless conversion of the option, nor vesting terms — those details would be needed to assess potential future stock sales.